Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 12/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365946 | 1.00 | GHSR (0.64) | GHSR | |
| SCHEMBL29414549 | 0.95 | GHSR (0.61) | GHSR | |
| SCHEMBL30276253 | 0.94 | GHSR (0.64) | GHSR | |
| SCHEMBL29551293 | 0.94 | GHSR (0.64) | GHSR | |
| SCHEMBL29754403 | 0.94 | GHSR (0.57) | GHSR | |
| SCHEMBL29366876 | 0.94 | GHSR (0.60) | GHSR | |
| SCHEMBL29507073 | 0.94 | GHSR (0.60) | GHSR | |
| SCHEMBL31632621 | 0.94 | GHSR (0.63) | GHSR | |
| SCHEMBL30276276 | 0.94 | GHSR (0.63) | GHSR | |
| SCHEMBL30490002 | 0.93 | GHSR (0.66) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656654-A1 | SOMATOSTATIN PEPTIDE ANALOGUE, CHELATE AND USE THEREOF | Qianhangjiang Pharmaceutical Co., Ltd. (CN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250345385-A1 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | CAMURUS AB (SE) | 2025-11-13 | — | — | US | disclosed |
| CN-120131956-A | Use of growth hormone inhibitors, and pharmaceutical compositions, formulations, and devices containing growth hormone inhibitors | 中山大学中山眼科中心 | 2025-06-13 | — | — | CN | disclosed |
| CN-119950770-A | Freeze-dried medicine box for preparing radiopharmaceuticals and preparation method and application thereof | 原子高科股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025066894-A1 | SOMATOSTATIN PEPTIDE ANALOGUE, CHELATE AND USE THEREOF | 钱杭江医药科技(嘉兴)有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119708199-A | Somatostatin peptide analogue, chelate and application thereof | 钱杭江医药科技(嘉兴)有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-12257282-B2 | Mixtures and formulations | CAMARUS AB (SE) | 2025-03-25 | — | — | US | disclosed |
| EP-4427814-A2 | CONTROLLED RELEASE PEPTIDE FORMULATIONS | Camurus AB (SE) | 2024-09-11 | — | — | EP | disclosed |
| US-20230372436-A1 | SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS | CAMURUS AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230285502-A1 | MIXTURES AND FORMULATIONS | CAMURUS AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-11672843-B2 | Somatostatin receptor agonist formulations | CAMURUS AB (SE) | 2023-06-13 | — | — | US | disclosed |
| US-11564968-B2 | Formulations containing a somatostatin receptor agonist | CAMURUS AB (SE) | 2023-01-31 | — | — | US | disclosed |
| US-11433120-B2 | Controlled release peptide formulations | CAMURUS AB (SE) | 2022-09-06 | — | — | US | disclosed |
| US-20220257694-A1 | MIXTURES AND FORMULATIONS | CAMURUS AB (SE) | 2022-08-18 | — | — | US | disclosed |
| US-20220168381-A1 | FORMULATIONS CONTAINING A SOMATOSTATIN RECEPTOR AGONIST | CAMURUS AB (SE) | 2022-06-02 | — | — | US | disclosed |
| EP-3236937-B1 | CONTROLLED-RELEASE FORMULATIONS | CAMURUS AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| US-11261215-B2 | Somatostatin prodrugs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-03-01 | — | — | US | disclosed |
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | CAMURUS AB (SE) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564968-B2 | Formulations containing a somatostatin receptor agonist | SSTR1, SSTR3, SSTR5 | GHSR 16/4885 |
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | PHOSPHO1, LIPA, ABHD16A | GHSR 2869/4885 |
| US-11261215-B2 | Somatostatin prodrugs | VIP, SSTR4, SSTR5 | GHSR 18/4885 |
| US-20220257694-A1 | MIXTURES AND FORMULATIONS | PHOSPHO1, LIPA, SGMS1 | GHSR 3271/4885 |
| US-20230285502-A1 | MIXTURES AND FORMULATIONS | PHOSPHO1, LIPA, SGMS1 | GHSR 3271/4885 |
| US-20230372436-A1 | SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS | SSTR1, SSTR5, SSTR3 | GHSR 29/4885 |
| US-12257282-B2 | Mixtures and formulations | PHOSPHO1, TTPA, LIPC | GHSR 4229/4885 |
| US-11672843-B2 | Somatostatin receptor agonist formulations | SSTR1, SSTR5, SSTR3 | GHSR 29/4885 |
| US-20250345385-A1 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | PHOSPHO1, LIPA, ABHD16A | GHSR 2892/4885 |
| US-20220168381-A1 | FORMULATIONS CONTAINING A SOMATOSTATIN RECEPTOR AGONIST | SSTR1, SSTR3, SSTR5 | GHSR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.